Navigation Links
Hadasit Bio-Holdings' Portfolio Companies Receive Funding to Support Clinical Trial Preparations and Obtain Regulatory Approvals in U.S. and Europe
Date:1/22/2013

JERUSALEM, Jan. 22, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that two of its portfolio companies, ProtAb and Enlivex, have received approximately $700,000 in convertible loans from Hadasit Bio-Holdings and its partners.  ProtAb received $435,000 and Enlivex received approximately $268,000 (NIS 1 million).

Ophir Shahaf , Chief Executive Officer of Hadasit Bio-Holdings, commented, "This recent influx of financing is intended to support and supplement the ongoing research and advancements within both companies. In regards to ProtAb, our partners at Clal Biotechnology Industries and Pontifax have also made proportionate financial commitments in an effort to fund the company in this same regard.  With the allocation of this capital, we aspire to develop a new form of treatment for autoimmune diseases that will activate the body's natural anti-inflammatory pathways.  ProtAb's activities are already focused on pin-pointing the mechanism of action for this treatment and preparing for clinical trials."

Mr. Shahaf continued, "At Enlivex, a company in which Hadasit currently holds a 92% stake, the funding was provided entirely by Hadasit Bio-Holdings.  This funding will help Enlivex continue to develop its unique solution for the prevention of Graft versus Host Disease (GVHD) for patients undergoing bone marrow transplants, for which no effective cure currently exists.  Throughout 2013, we anticipate Enlivex to obtain orphan drug status in Europe and the U.S., present clinical plans for FDA approval, as well as make preparations for a multi-center Phase II trial.  We extensively analyzed their progress and future prospects, and we maintain complete certainty that these milestones will be completed in a year's time.  We know that each individual success will add significant value to Enlivex as well as Hadasit Bio-Holdings and its shareholders."

"Throughout 2012, both portfolio companies have undergone significant advancements and received about NIS 7.5 million, including substantial funding from the Israeli Chief Scientist's Office. With the implementation of this financing package we hope to augment their ongoing clinical and business developments and ultimately create value for both of these companies," concluded Mr. Shahaf.

For more information on Enlivex please visit: Enlivex

For more information on ProtAb please visit: ProtAb

About Hadasit Bio-Holdings

Hadasit Bio-Holdings, Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle of six portfolio biotech companies all based on inventions developed by Hadassah.  Hadasit Bio-Holdings focuses on advancing companies that have already shown proof of concept and successful preclinical trials to completion of Phase I/II.

The portfolio companies develop drugs with blockbuster potential (targeting markets that are worth over a billion dollars) operating in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader. The company is managed by Ophir Shahaf .

For more information please visit: www.hbl.co.il

Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212-896-1233 / 1239
pcarlson@kcsa.com / jdver@kcsa.com


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems, LLC Cites Broad Applications of its 2013 Harvest of Uniquely Valuable Hemp Oil
2. VWR International, LLC Expands European Portfolio With Acquisitions Of Labonord SAS And Switch BVBA
3. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
4. SAFC Expands PharmaGrade Raw Materials Portfolio for Biopharmaceutical Manufacturing
5. Positioning Strategies Effectively Minimize Cannibalization of a Legacy Brand When Expanding a Product Portfolio
6. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
7. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
8. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
9. PhytoSPHERE Systems, a Medical Marijuana Inc Portfolio Company, to Bring Production Facilities to Europe through Canipa Holdings.
10. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
11. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):